ID   Ma-Mel-30
AC   CVCL_A165
SY   Ma-Mel_30; Ma-Mel 30; MaMel-30; MaMel30
DR   cancercelllines; CVCL_A165
DR   Cosmic; 1467749
DR   Cosmic; 2163817
DR   Cosmic; 2686392
DR   ESTDAB; ESTDAB-104
DR   GEO; GSM109060
DR   GEO; GSM437000
DR   Progenetix; CVCL_A165
DR   Wikidata; Q54903783
RX   PubMed=15592718;
RX   PubMed=16827748;
RX   PubMed=17311103;
RX   PubMed=20544847;
RX   PubMed=23348503;
RX   PubMed=23851445;
RX   PubMed=26909863;
CC   HLA typing: A*02:01,26:12; B*57:01; C*06:02; DPB1*04:01,03:01; DQB1*03:03:02; DRB1*07:01 (PubMed=15592718).
CC   Sequence variation: Gene deletion; HGNC; HGNC:1787; CDKN2A; Zygosity=Homozygous (PubMed=26909863).
CC   Sequence variation: Gene deletion; HGNC; HGNC:1788; CDKN2B; Zygosity=Homozygous (PubMed=26909863).
CC   Sequence variation: Gene fusion; HGNC; HGNC:7413; MTAP + HGNC; HGNC:34341; CDKN2B-AS1; Name(s)=MTAP-ANRIL (PubMed=26909863).
CC   Sequence variation: Mutation; HGNC; HGNC:1097; BRAF; Simple; p.Asp594Asn (c.1780G>A); ClinVar=VCV000044813; Zygosity=Unspecified (PubMed=16827748; PubMed=17311103; PubMed=23348503; PubMed=23851445).
CC   Sequence variation: Mutation; HGNC; HGNC:7989; NRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000013901; Zygosity=Unspecified (PubMed=17311103; PubMed=23348503).
CC   Omics: Transcriptomics; Microarray.
CC   Omics: Variations; SNP array analysis.
CC   Derived from site: Metastatic; Hypodermis; UBERON=UBERON_0002072.
CC   Derived from site: Metastatic; Skin; UBERON=UBERON_0002097.
ST   Source(s): ESTDAB=ESTDAB-104
ST   Amelogenin: X,Y
ST   CSF1PO: 12,13
ST   D13S317: 10,11
ST   D3S1358: 16
ST   D5S818: 12,13
ST   D7S820: 11
ST   FGA: 21,23.2
ST   TH01: 9.3
ST   TPOX: 8,11
ST   vWA: 16,17
DI   NCIt; C4022; Acral lentiginous melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   58Y
CA   Cancer cell line
DT   Created: 06-06-12; Last updated: 10-04-25; Version: 22
//
RX   PubMed=15592718; DOI=10.1007/s00262-004-0561-5; PMCID=PMC11032966;
RA   Rodriguez T., Mendez R., Roberts C.H., Ruiz-Cabello Osuna F., Dodi I.A.,
RA   Lopez-Nevot M.A., Paco L., Maleno I., Marsh S.G.E., Pawelec G.,
RA   Garrido F.;
RT   "High frequency of homozygosity of the HLA region in melanoma cell
RT   lines reveals a pattern compatible with extensive loss of
RT   heterozygosity.";
RL   Cancer Immunol. Immunother. 54:141-148(2005).
//
RX   PubMed=16827748; DOI=10.1111/j.1600-0749.2006.00322.x;
RA   Hoek K.S., Schlegel N.C., Brafford P., Sucker A., Ugurel S., Kumar R.,
RA   Weber B.L., Nathanson K.L., Phillips D.J., Herlyn M., Schadendorf D.,
RA   Dummer R.;
RT   "Metastatic potential of melanomas defined by specific gene expression
RT   profiles with no BRAF signature.";
RL   Pigment Cell Res. 19:290-302(2006).
//
RX   PubMed=17311103; DOI=10.1371/journal.pone.0000236; PMCID=PMC1794595;
RA   Ugurel S., Thirumaran R.K., Bloethner S., Gast A., Sucker A.,
RA   Mueller-Berghaus J., Rittgen W., Hemminki K., Becker J.C., Kumar R.,
RA   Schadendorf D.;
RT   "B-RAF and N-RAS mutations are preserved during short time in vitro
RT   propagation and differentially impact prognosis.";
RL   PLoS ONE 2:e236.1-e236.13(2007).
//
RX   PubMed=20544847; DOI=10.1002/gcc.20785;
RA   Gast A., Scherer D., Chen B.-W., Bloethner S., Melchert S., Sucker A.,
RA   Hemminki K., Schadendorf D., Kumar R.;
RT   "Somatic alterations in the melanoma genome: a high-resolution
RT   array-based comparative genomic hybridization study.";
RL   Genes Chromosomes Cancer 49:733-745(2010).
//
RX   PubMed=23348503; DOI=10.1126/science.1230062;
RA   Horn S., Figl A., Rachakonda P.S., Fischer C., Sucker A., Gast A.,
RA   Kadel S., Moll I., Nagore E., Hemminki K., Schadendorf D., Kumar R.;
RT   "TERT promoter mutations in familial and sporadic melanoma.";
RL   Science 339:959-961(2013).
//
RX   PubMed=23851445; DOI=10.1158/1541-7786.MCR-13-0006;
RA   Dahl C., Christensen C., Jonsson G., Lorentzen A., Skjodt M.L.,
RA   Borg A., Pawelec G., Guldberg P.;
RT   "Mutual exclusivity analysis of genetic and epigenetic drivers in
RT   melanoma identifies a link between p14 ARF and RARbeta signaling.";
RL   Mol. Cancer Res. 11:1166-1178(2013).
//
RX   PubMed=26909863; DOI=10.18632/oncotarget.7503; PMCID=PMC4941330;
RA   Xie H.-P., Rachakonda P.S., Heidenreich B., Nagore E., Sucker A.,
RA   Hemminki K., Schadendorf D., Kumar R.;
RT   "Mapping of deletion breakpoints at the CDKN2A locus in melanoma:
RT   detection of MTAP-ANRIL fusion transcripts.";
RL   Oncotarget 7:16490-16504(2016).
//